Violence, Mental Health and HIV: Impact of CETA on viral suppression and retention
We will test CETA’s effectiveness at increasing viral suppression and reducing violence in a community-based randomized trial of 400 HIV-infected women who have recently experienced IPV, with CETA delivered to them alone or with their male partners (with at least 75 women with partners). Our aims are:
Aim 1: Among HIV-infected women on ART who have experienced IPV and have an unsuppressed viral load, we will assess the effectiveness of CETA vs. active control at increasing the proportion retained and virally suppressed by 12 months and at decreasing the severity of IPV and other mental and behavioral health problems using an individually randomized trial. Hypothesis: CETA will improve retention and suppression and reduce IPV, mental, and behavioral health problems vs. active control.
Aim 2: To identify mediators and moderators of CETA’s effect on the primary outcome (retention and viral suppression by 12 months). Our primary mediator will be IPV and primary moderator will be partner involvement. Hypothesis: Reduction in IPV after CETA will mediate improvement in retention and viral suppression among women who receive CETA; partner involvement in CETA will increase the effect size.
Aim 3: To assess the cost and cost-effectiveness of CETA vs. active control at increasing the proportion of unsuppressed women who have experienced IPV who are retained and virally suppressed by 12 months. Hypothesis: CETA will involve additional costs vs. standard of care but with better retention and viral suppression at 12 months, making it cost effective.